Yue Xiang Yue Health Submits IPO Prospectus in June 2026
Barty Medical
Vascular Interventional and Implantable Device R&D Manufacturer
Vivolight
Developer of Biomedical Optical Imaging Systems
Highlightll Pharma
Innovative Drug Developer
Trinomab
Developer of Natural Fully Human Monoclonal Antibody New Drugs
SPH
Pharmaceutical R&D and Manufacturing
Atom Therapeutics
Innovative Drug Developer
Click to Follow | Focused on Global Biopharma Investment
On June 10, 2026, the "Shenzhen Yifeng Mingyuan Seed Venture Capital Partnership (Limited Partnership)," established with participation from the Shenzhen Science and Technology Innovation Seed Fund, officially completed its industrial and commercial registration, marking a critical step for Yifeng Capital in its early-stage investment strategy.
Notably, Yifeng Capital’s portfolio ecosystem has seen a surge of positive developments this month, with multiple investee companies achieving breakthroughs in advancing financing rounds and expanding core businesses. The overall investment ecosystem is accelerating into a phase of tangible returns.
Xihu Biotech
· Westlake Biologics Completes Financing Round Exceeding RMB 100 Million
Westlake Biology Announces Completion of New Strategic Financing Round Exceeding RMB 100 Million; Existing Shareholder Yifeng Capital Continues to Increase Investment
Carbon: The Origin of All Things
· Carbon Life Completes Series A Financing
Tansheng Wanwu Completes Series A FinancingRecently, Tansheng Wanwu completed its Series A financing round. The round was invested by institutions including Yifeng Capital and Boyuan Capital.
Barty Medical
· Barty Medical Completes Nearly RMB 200 Million in Series D Financing
Recently, Barty Medical completed a Series D financing round of nearly RMB 200 million, accelerating the commercialization and globalization of innovative pan-vascular interventional devices.
Ruijiakang
· Ruijiakang Secures Additional Funding
Recently, Wuhan Ruijiakang secured Series B funding from Yifeng Zhuohua Fund. The funds raised in this round will be primarily used for the "10,000-ton-scale Demonstration Base for Non-grain Biological Manufacturing of Bio-based Platform Compounds" project.
Vivolight
· Completed hundreds of millions in financing
Vivolight Completes New Round of Financing Worth Hundreds of MillionsRecently, Vivolight completed a new round of financing amounting to hundreds of millions of yuan. This round was co-led by China-US Green Yangtze River Delta Fund and Yifeng Capital.
Highlightll Pharma
· Highlightll Pharma Files for Hong Kong IPO
On June 8, the HKEX website showed that Highlightll Pharma submitted an IPO application.
Xihu Biotech
· Westlake Biologics Completes Financing Round Exceeding RMB 100 Million
Xihu Biotech
· Westlake Biologics Completes Financing Round Exceeding RMB 100 Million
Westlake Biology Announces Completion of New Strategic Financing Round Exceeding RMB 100 Million; Existing Shareholder Yifeng Capital Continues to Increase Investment
Carbon: The Origin of All Things
· Carbon Life Completes Series A Financing
Carbon: The Origin of All Things
· Carbon Life Completes Series A Financing
Tansheng Wanwu Completes Series A FinancingRecently, Tansheng Wanwu completed its Series A financing round. The round was invested by institutions including Yifeng Capital and Boyuan Capital.
Barty Medical
· Barty Medical Completes Nearly RMB 200 Million in Series D Financing
Barty Medical
· Barty Medical Completes Nearly RMB 200 Million in Series D Financing
Recently, Barty Medical completed a Series D financing round of nearly RMB 200 million, accelerating the commercialization and globalization of innovative pan-vascular interventional devices.
Ruijiakang
· Ruijiakang Secures Additional Funding
Ruijiakang
· Ruijiakang Secures Additional Funding
Recently, Wuhan Ruijiakang secured Series B funding from Yifeng Zhuohua Fund. The funds raised in this round will be primarily used for the "10,000-ton-scale Demonstration Base for Non-grain Biological Manufacturing of Bio-based Platform Compounds" project.
Vivolight
· Completed hundreds of millions in financing
Vivolight
· Completed hundreds of millions in financing
Vivolight Completes New Round of Financing Worth Hundreds of MillionsRecently, Vivolight completed a new round of financing amounting to hundreds of millions of yuan. This round was co-led by China-US Green Yangtze River Delta Fund and Yifeng Capital.
Highlightll Pharma
· Highlightll Pharma Files for Hong Kong IPO
Highlightll Pharma
· Highlightll Pharma Files for Hong Kong IPO
On June 8, the HKEX website showed that Highlightll Pharma submitted an IPO application.
Highlightll Pharma
· JAK1/TYK2 Proposed for Breakthrough Therapy Designation
Highlightll Pharma
· JAK1/TYK2 Proposed for Breakthrough Therapy Designation
Highlightll Pharma
· JAK1/TYK2 Proposed for Breakthrough Therapy Designation
On June 24, 2026, Highlightll Pharma’s JAK1/TYK2 inhibitor TLL-018 tablets were proposed for inclusion in the Breakthrough Therapy Designation program for the treatment of rheumatoid arthritis.
Trinomab
· Partnering with SPH to Accelerate the Global Rollout of the Next-Generation “Tetanus Shot,” Staidumab
Trinomab
· Partnering with SPH to Accelerate the Global Rollout of the Next-Generation “Tetanus Shot,” Staidumab
Trinomab and SPH’s International Business Division Hold Signing Ceremony in Shanghai for Strategic Cooperation on the Commercialization of Stalatumab in the Philippines
Huayuan Regeneration
· Attending ISO 2026: Discussing Frontier Explorations in Kidney Disease Treatment
Huayuan Regeneration
· Attending ISO 2026: Discussing Frontier Explorations in Kidney Disease Treatment
June 11–12, the ISO 2026 Fifth Stem Cell Therapy and Organoid In-Depth Focus Forum was held in Beijing.Dr. Liu Yajing, Vice President of R&D at Huayuan Regenerative Cells, participated extensively in the sub-forum on “Development of iPSC-Derived Stem Cell Therapies.”
Kento Fluid
· The New MAP96 Pipette Has Arrived with a Fresh Look
June 11–12, the ISO 2026 Fifth Stem Cell Therapy and Organoid In-Depth Focus Forum was held in Beijing.Dr. Liu Yajing, Vice President of R&D at Huayuan Regenerative Cells, participated extensively in the sub-forum on “Development of iPSC-Derived Stem Cell Therapies.”
June 11–12, the ISO 2026 Fifth Stem Cell Therapy and Organoid In-Depth Focus Forum was held in Beijing.Dr. Liu Yajing, Vice President of R&D at Huayuan Regenerative Cells, participated extensively in the sub-forum on “Development of iPSC-Derived Stem Cell Therapies.”
Kento Fluid
· The New MAP96 Pipette Has Arrived with a Fresh Look
Kento Fluid
· The New MAP96 Pipette Has Arrived with a Fresh Look
Recently, the new version of KENTOP MAP96 pipettes has been launched.
Atom Therapeutics
· New Anti-Gout Drug Launches Phase III Clinical Trial in China
Atom Therapeutics
· New Anti-Gout Drug Launches Phase III Clinical Trial in China
Atom Therapeutics
· New Anti-Gout Drug Launches Phase III Clinical Trial in China
Atom Therapeutics
· New Anti-Gout Drug Launches Phase III Clinical Trial in China
On June 23, Atom Therapeutics announced that its independently developed innovative small-molecule drug for gout, ABP-671 (lingdolinurad), has initiated Phase III clinical trials in China, with the first patient enrolled and dosed.
Kening Bio
· Launch of the First-in-Human Clinical Trial for Dry Eye Disease
Kening Bio
· Launch of the First-in-Human Clinical Trial for Dry Eye Disease
Kening Bio
· Launch of the First-in-Human Clinical Trial for Dry Eye Disease
Recently, Kening Biologics announced that the first subject in its first-in-human (FIH) clinical trial for dry eye disease has completed dosing.
Huamei Haolian
· Invited to Attend the AI+ Empowering Alumni Development Forum
Huamei Haolian
· Invited to Attend the AI+ Empowering Alumni Development Forum
Huamei Haolian
· Invited to Attend the AI+ Empowering Alumni Development Forum
Recently, Huamei Haolian was invited to attend the AI+ Empowering Alumni Development Forum, discussing how AI-driven health management is reshaping the value chain of the medical ecosystem.
· Debut at the HKU Business and Economics Forum
On the afternoon of June 13, the thematic forum “Smart Innovation in Healthcare, Prosperity and Well-being for the People” was held in Hong Kong. Xu Bingyu, Founder and CEO of Huamei Haolian, attended the event and delivered a keynote speech.
· Debut at the HKU Business and Economics Forum
On the afternoon of June 13, the thematic forum “Smart Innovation in Healthcare, Prosperity and Well-being for the People” was held in Hong Kong. Xu Bingyu, Founder and CEO of Huamei Haolian, attended the event and delivered a keynote speech.
Tianqin Biologics
· Tianqin Biologics’ NHP Metabolic Model Debuts at the ADA Annual Meeting
Tianqin Biologics
· Tianqin Biologics’ NHP Metabolic Model Debuts at the ADA Annual Meeting
Tianqin Biologics
· Tianqin Biologics’ NHP Metabolic Model Debuts at the ADA Annual Meeting
Recently, at the 86th Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, USA, Tianqin Biologics’ independently developed non-human primate (NHP) models of metabolic diseases attracted widespread attention.
· Supporting the Clinical Trial Approval of Mabwell’s Innovative Drug 9MW5211
Recently, Mabwell Bioscience announced that the Investigational New Drug (IND) application for its innovative drug 9MW5211 has been officially cleared by the U.S. Food and Drug Administration (FDA). Tianqin Xinsheng, a wholly-owned subsidiary of Tianqin Biology, provided comprehensive toxicology research services for this project.
Hannuo Medical
· Building a Global ECMO Expert Platform
Hannuo Medical
· Building a Global ECMO Expert Platform
From June 11 to 13, the 8th Annual Conference of the Asia-Pacific Extracorporeal Life Support Organization was held in Japan. At the event, Hanuo Medical prominently showcased the multi-modal conversion capabilities of its Lifemotion ECMO system.
Lingyi Biologics
· Debut at the 3rd International GBA1 Conference
Lingyi Biologics
· Debut at the 3rd International GBA1 Conference
Lingyi Bio Debuts at the 3rd International GBA1 Conference, Showcasing Latest Advances in Gene Therapy Research for GBA1-Related Parkinson’s Disease
Jingwei Shida
· Debut at the 23rd Beijing International Digestive Disease Forum
Jingwei Shida
· Debut at the 23rd Beijing International Digestive Disease Forum
Jingwei Shida
· Debut at the 23rd Beijing International Digestive Disease Forum
On June 14, the 2026 World Chinese Digestive Physicians Annual Conference and the 23rd Beijing International Digestive Diseases Forum concluded in Beijing. Jingwei Shida engaged in discussions with clinical experts on multiple dimensions, including the development of the WEO-ERCP training system, to jointly explore new pathways for the standardized and precise advancement of digestive endoscopy.
Zifu Medical
· Debut at the 2026 Hangzhou Endoscopy Conference
On June 4, the 3rd Conference on Medical Endoscopy Technology Development and the 1st Medical Surgical Robotics Forum were held in Hangzhou. Zifu Medical was invited to attend the conference and delivered a thematic presentation.
Zifu Medical
· Debut at the 2026 Hangzhou Endoscopy Conference
On June 4, the 3rd Conference on Medical Endoscopy Technology Development and the 1st Medical Surgical Robotics Forum were held in Hangzhou. Zifu Medical was invited to attend the conference and delivered a thematic presentation.
Real Biotech
· Debut at the ASCO Annual Meeting
Recently, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in the United States. Real Biotech, in collaboration with Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, presented Phase I clinical study data on azvudine in patients with advanced solid tumors in a poster presentation.
Tianguang Medino
· Debut at the 2026 BIO International Convention
From June 22 to 25, Tiangang Yinuov made its debut at the 2026 BIO International Convention in the United States, where Dr. Yin Liusong, Chief Scientific Officer, delivered a public presentation.
Pinshan Bio
· Signed a strategic cooperation agreement with Ripple Gold
Recently, Pinshan Biotech and Repligen officially signed a strategic cooperation agreement, announcing in-depth collaboration in the field of hollow fiber filter products.
Saiyuan Biotech
· Partnering with Walvax to Accelerate Clinical Research on in vivo CAR Immune Cell Therapy
Recently, Saiyuan Biotech and Walvax Biotechnology officially signed a project collaboration and development agreement. The two parties will focus on in vivo CAR therapies based on the mRNA-LNP technology platform and jointly advance investigator-initiated trials (IIT) for the treatment of hepatocellular carcinoma solid tumors.
· Featured at the 2026 ASCO Annual Meeting
Recently, the founding team of Saiyuan Bioscience presented two latest research reports on tumor immune cell therapy at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, USA.
Ailios
· Shining at CPHI China 2026
From June 16 to 18, the 24th World Pharmaceutical Raw Materials China Exhibition was held in Shanghai. Ailios showcased its comprehensive end-to-end filtration solutions, covering depth filtration, liquid pre-filtration, sterilizing-grade filtration, and hardware systems.
Neurate
· Debut at Asia-Pacific’s Premier Academic Platform
From June 11 to 14, the 20th Asia-Pacific Conference on Cardiovascular and Interventional Radiology was held in Suzhou. Nuiruite Medical systematically showcased its forward-looking layout and key technological achievements in the field of interventional radiology and nuclear medicine at this conference.
Carbon Creates All Things
· Ningdong 1,000-ton e-SAF Project Breaks Ground
On June 16, the “Carbon to Everything” thousand-ton-scale Direct Air Capture (DAC) project for producing sustainable aviation fuel (e-SAF) officially commenced construction at the Ningdong Energy and Chemical Industry Base in Ningxia.
Bokang Shiyun
· Global innovative ophthalmic drug CBT-001 completes enrollment of all patients in its international multicenter Phase III clinical trial
Recently, Bokon Vision announced that its global innovative ophthalmic drug CBT-001, developed for the treatment of pterygium, has completed the enrollment of all patients at global sites in its international multicenter Phase III clinical trial.
Huiyuan Biologics
· On the Frontlines: Technology Empowerment Sub-forum at the Annual Conference of Chinese Hospital Presidents
From June 5 to 7, the 20th Annual Conference of Chinese Hospital Presidents was grandly held at the Xiamen International Expo Center. Heyuan Biotech showcased Aofumin® at the “Technology Empowerment” sub-forum.
Huahao Zhongtian
· Featured at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating its core product, utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast CancerLatest Data from the FRUTD-001 Study.
Real Biotech
· Debut at the ASCO Annual Meeting
Recently, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in the United States. Real Biotech, in collaboration with Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, presented Phase I clinical study data on azvudine in patients with advanced solid tumors in a poster presentation.
Real Biotech
· Debut at the ASCO Annual Meeting
Recently, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in the United States. Real Biotech, in collaboration with Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, presented Phase I clinical study data on azvudine in patients with advanced solid tumors in a poster presentation.
Tianguang Medino
· Debut at the 2026 BIO International Convention
From June 22 to 25, Tiangang Yinuov made its debut at the 2026 BIO International Convention in the United States, where Dr. Yin Liusong, Chief Scientific Officer, delivered a public presentation.
Tianguang Medino
· Debut at the 2026 BIO International Convention
From June 22 to 25, Tiangang Yinuov made its debut at the 2026 BIO International Convention in the United States, where Dr. Yin Liusong, Chief Scientific Officer, delivered a public presentation.
Pinshan Bio
· Signed a strategic cooperation agreement with Ripple Gold
Recently, Pinshan Biotech and Repligen officially signed a strategic cooperation agreement, announcing in-depth collaboration in the field of hollow fiber filter products.
Pinshan Bio
· Signed a strategic cooperation agreement with Ripple Gold
Recently, Pinshan Biotech and Repligen officially signed a strategic cooperation agreement, announcing in-depth collaboration in the field of hollow fiber filter products.
Saiyuan Biotech
· Partnering with Walvax to Accelerate Clinical Research on in vivo CAR Immune Cell Therapy
Recently, Saiyuan Biotech and Walvax Biotechnology officially signed a project collaboration and development agreement. The two parties will focus on in vivo CAR therapies based on the mRNA-LNP technology platform and jointly advance investigator-initiated trials (IIT) for the treatment of hepatocellular carcinoma solid tumors.
· Featured at the 2026 ASCO Annual Meeting
Recently, the founding team of Saiyuan Bioscience presented two latest research reports on tumor immune cell therapy at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, USA.
Saiyuan Biotech
· Partnering with Walvax to Accelerate Clinical Research on in vivo CAR Immune Cell Therapy
Recently, Saiyuan Biotech and Walvax Biotechnology officially signed a project collaboration and development agreement. The two parties will focus on in vivo CAR therapies based on the mRNA-LNP technology platform and jointly advance investigator-initiated trials (IIT) for the treatment of hepatocellular carcinoma solid tumors.
· Featured at the 2026 ASCO Annual Meeting
Recently, the founding team of Saiyuan Bioscience presented two latest research reports on tumor immune cell therapy at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, USA.
Ailios
· Shining at CPHI China 2026
From June 16 to 18, the 24th World Pharmaceutical Raw Materials China Exhibition was held in Shanghai. Ailios showcased its comprehensive end-to-end filtration solutions, covering depth filtration, liquid pre-filtration, sterilizing-grade filtration, and hardware systems.
Ailios
· Shining at CPHI China 2026
From June 16 to 18, the 24th World Pharmaceutical Raw Materials China Exhibition was held in Shanghai. Ailios showcased its comprehensive end-to-end filtration solutions, covering depth filtration, liquid pre-filtration, sterilizing-grade filtration, and hardware systems.
Neurate
· Debut at Asia-Pacific’s Premier Academic Platform
From June 11 to 14, the 20th Asia-Pacific Conference on Cardiovascular and Interventional Radiology was held in Suzhou. Nuiruite Medical systematically showcased its forward-looking layout and key technological achievements in the field of interventional radiology and nuclear medicine at this conference.
Neurate
· Debut at Asia-Pacific’s Premier Academic Platform
From June 11 to 14, the 20th Asia-Pacific Conference on Cardiovascular and Interventional Radiology was held in Suzhou. Nuiruite Medical systematically showcased its forward-looking layout and key technological achievements in the field of interventional radiology and nuclear medicine at this conference.
Carbon Creates All Things
· Ningdong 1,000-ton e-SAF Project Breaks Ground
On June 16, the “Carbon to Everything” thousand-ton-scale Direct Air Capture (DAC) project for producing sustainable aviation fuel (e-SAF) officially commenced construction at the Ningdong Energy and Chemical Industry Base in Ningxia.
Bokang Shiyun
· Global innovative ophthalmic drug CBT-001 completes enrollment of all patients in its international multicenter Phase III clinical trial
Recently, Bokon Vision announced that its global innovative ophthalmic drug CBT-001, developed for the treatment of pterygium, has completed the enrollment of all patients at global sites in its international multicenter Phase III clinical trial.
Carbon Creates All Things
· Ningdong 1,000-ton e-SAF Project Breaks Ground
On June 16, the “Carbon to Everything” thousand-ton-scale Direct Air Capture (DAC) project for producing sustainable aviation fuel (e-SAF) officially commenced construction at the Ningdong Energy and Chemical Industry Base in Ningxia.
Bokang Shiyun
· Global innovative ophthalmic drug CBT-001 completes enrollment of all patients in its international multicenter Phase III clinical trial
Recently, Bokon Vision announced that its global innovative ophthalmic drug CBT-001, developed for the treatment of pterygium, has completed the enrollment of all patients at global sites in its international multicenter Phase III clinical trial.
Huiyuan Biologics
· On the Frontlines: Technology Empowerment Sub-forum at the Annual Conference of Chinese Hospital Presidents
Huiyuan Biologics
· On the Frontlines: Technology Empowerment Sub-forum at the Annual Conference of Chinese Hospital Presidents
Huiyuan Biologics
· On the Frontlines: Technology Empowerment Sub-forum at the Annual Conference of Chinese Hospital Presidents
From June 5 to 7, the 20th Annual Conference of Chinese Hospital Presidents was grandly held at the Xiamen International Expo Center. Heyuan Biotech showcased Aofumin® at the “Technology Empowerment” sub-forum.
Huahao Zhongtian
· Featured at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating its core product, utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast CancerLatest Data from the FRUTD-001 Study.
Huahao Zhongtian
· Featured at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating its core product, utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast CancerLatest Data from the FRUTD-001 Study.
Huahao Zhongtian
· Featured at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating its core product, utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast CancerLatest Data from the FRUTD-001 Study.
Huahao Zhongtian
· Featured at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating its core product, utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast CancerLatest Data from the FRUTD-001 Study.
Pulai Pharma
· World’s First Gananin-Class Antimicrobial Peptide New Drug Approved for Market Launch
On June 17, Puyi Ke®, China’s first Class 1 innovative drug in the granulin-class antimicrobial peptide category, independently developed by Pulai Pharmaceutical, received marketing approval from the National Medical Products Administration (NMPA).
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, the “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit,” independently developed by Ruijing Biotech, received Class III Medical Device Registration Certification from the National Medical Products Administration (NMPA). It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, utidelone capsules (UTD2), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Vivolight
· Domestically Developed 355nm Cold Laser Ablation Device Approved for Market Launch
Recently, FastErazer, a triple-frequency Nd:YAG laser ablation device independently developed by Vivolight’s subsidiary Zhongke Rongguang, has officially received market approval from the National Medical Products Administration.
Tingsheng Technology
· No.7FundICEProductTINGSN Sonic Eyes 8 Pro Approved
On June 23, Tingsheng Technology’s TINGSN Sonic Eyes 8 Pro single-use intracardiac echocardiography diagnostic catheter officially received approval from the National Medical Products Administration (NMPA), successfully obtaining a Class III medical device registration certificate.
Xuanyu Medical
· StrenSoft™ Adjustable-Curved Pulmonary Artery Embolectomy Stent System Officially ApprovedNMPA
On June 1, the StrenSoft™ Adjustable-Curve Pulmonary Artery Embolectomy Stent System, independently developed by Xuanyu Medical, officially received market approval from the National Medical Products Administration (NMPA).
Reindeer Biologics
· New Drug Application for Ikioluncept Injection Officially Approved by Singapore’s Health Sciences Authority
On June 18, Xunlu Bio announced that the Health Sciences Authority (HSA) of Singapore has officially approved its New Drug Application (NDA) for Iqocicel Injection, a fully human anti-BCMA CAR-T cell therapy product independently developed by the company.
Pulai Pharma
· World’s First Gananin-Class Antimicrobial Peptide New Drug Approved for Market Launch
On June 17, Puyi Ke®, China’s first Class 1 innovative drug in the granulin-class antimicrobial peptide category, independently developed by Pulai Pharmaceutical, received marketing approval from the National Medical Products Administration (NMPA).
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, the “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit,” independently developed by Ruijing Biotech, received Class III Medical Device Registration Certification from the National Medical Products Administration (NMPA). It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, utidelone capsules (UTD2), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Vivolight
· Domestically Developed 355nm Cold Laser Ablation Device Approved for Market Launch
Recently, FastErazer, a triple-frequency Nd:YAG laser ablation device independently developed by Vivolight’s subsidiary Zhongke Rongguang, has officially received market approval from the National Medical Products Administration.
Tingsheng Technology
· No.7FundICEProductTINGSN Sonic Eyes 8 Pro Approved
On June 23, Tingsheng Technology’s TINGSN Sonic Eyes 8 Pro single-use intracardiac echocardiography diagnostic catheter officially received approval from the National Medical Products Administration (NMPA), successfully obtaining a Class III medical device registration certificate.
Xuanyu Medical
· StrenSoft™ Adjustable-Curved Pulmonary Artery Embolectomy Stent System Officially ApprovedNMPA
On June 1, the StrenSoft™ Adjustable-Curve Pulmonary Artery Embolectomy Stent System, independently developed by Xuanyu Medical, officially received market approval from the National Medical Products Administration (NMPA).
Reindeer Biologics
· New Drug Application for Ikioluncept Injection Officially Approved by Singapore’s Health Sciences Authority
On June 18, Xunlu Bio announced that the Health Sciences Authority (HSA) of Singapore has officially approved its New Drug Application (NDA) for Iqocicel Injection, a fully human anti-BCMA CAR-T cell therapy product independently developed by the company.
Pulai Pharma
· World’s First Gananin-Class Antimicrobial Peptide New Drug Approved for Market Launch
On June 17, Puyi Ke®, China’s first Class 1 innovative drug in the granulin-class antimicrobial peptide category, independently developed by Pulai Pharmaceutical, received marketing approval from the National Medical Products Administration (NMPA).
Pulai Pharma
· World’s First Gananin-Class Antimicrobial Peptide New Drug Approved for Market Launch
On June 17, Puyi Ke®, China’s first Class 1 innovative drug in the granulin-class antimicrobial peptide category, independently developed by Pulai Pharmaceutical, received marketing approval from the National Medical Products Administration (NMPA).
Pulai Pharma
· World’s First Gananin-Class Antimicrobial Peptide New Drug Approved for Market Launch
On June 17, Puyi Ke®, China’s first Class 1 innovative drug in the granulin-class antimicrobial peptide category, independently developed by Pulai Pharmaceutical, received marketing approval from the National Medical Products Administration (NMPA).
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, the “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit,” independently developed by Ruijing Biotech, received Class III Medical Device Registration Certification from the National Medical Products Administration (NMPA). It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, utidelone capsules (UTD2), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, the “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit,” independently developed by Ruijing Biotech, received Class III Medical Device Registration Certification from the National Medical Products Administration (NMPA). It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, utidelone capsules (UTD2), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, the “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit,” independently developed by Ruijing Biotech, received Class III Medical Device Registration Certification from the National Medical Products Administration (NMPA). It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, utidelone capsules (UTD2), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Vivolight
· Domestically Developed 355nm Cold Laser Ablation Device Approved for Market Launch
Recently, FastErazer, a triple-frequency Nd:YAG laser ablation device independently developed by Vivolight’s subsidiary Zhongke Rongguang, has officially received market approval from the National Medical Products Administration.
Tingsheng Technology
· No.7FundICEProductTINGSN Sonic Eyes 8 Pro Approved
On June 23, Tingsheng Technology’s TINGSN Sonic Eyes 8 Pro single-use intracardiac echocardiography diagnostic catheter officially received approval from the National Medical Products Administration (NMPA), successfully obtaining a Class III medical device registration certificate.
Xuanyu Medical
· StrenSoft™ Adjustable-Curved Pulmonary Artery Embolectomy Stent System Officially ApprovedNMPA
On June 1, the StrenSoft™ Adjustable-Curve Pulmonary Artery Embolectomy Stent System, independently developed by Xuanyu Medical, officially received market approval from the National Medical Products Administration (NMPA).
Reindeer Biologics
· New Drug Application for Ikioluncept Injection Officially Approved by Singapore’s Health Sciences Authority
On June 18, Xunlu Bio announced that the Health Sciences Authority (HSA) of Singapore has officially approved its New Drug Application (NDA) for Iqocicel Injection, a fully human anti-BCMA CAR-T cell therapy product independently developed by the company.
Approval Granted for the Establishment of a Branch Postdoctoral Research Station
Wins the 2026 Global MedTech "Ophthalmic Innovative Device Award"
· Century Kangtai
Achieved a Perfect Score in the National Health Commission’s National Center for Clinical Laboratories (NCCL) – 2026 Pilot External Quality Assessment Program for High-Throughput Sequencing Detection of Solid Tumor Fusion Genes (RNA Level)
· Maijing Genomics
Molecular Lab Wins the “Reaching for the Moon Award” at the 2026 Insurance Technology Innovation Competition
· Huamei Haolian
Named to E-Drug Manager’s 2026 Top 100 Innovative Pharmaceutical Enterprises in China
· Ascentage Pharma, Tiangang Medical
Recognized as a Hangzhou “Good Seedling” Enterprise
· Westlake Omi
Appointed as Head of the Artificial Intelligence Department, 4th Executive Committee of CCI
· Zhu Rui, Chairman of Vivolight
Honored as Top 100 in R&D Strength for Chemical Drugs in 2026
· Beta Pharma
Honored as One of the Top 100 Seed Enterprises in China’s Pharmaceutical Innovation for 2026
· Highlightll Pharma
Approval Granted for the Establishment of a Branch Postdoctoral Research Station
Wins the 2026 Global MedTech "Ophthalmic Innovative Device Award"
· Century Kangtai
Achieved a Perfect Score in the National Health Commission’s National Center for Clinical Laboratories (NCCL) – 2026 Pilot External Quality Assessment Program for High-Throughput Sequencing Detection of Solid Tumor Fusion Genes (RNA Level)
· Maijing Genomics
Molecular Lab Wins the “Reaching for the Moon Award” at the 2026 Insurance Technology Innovation Competition
· Huamei Haolian
Named to E-Drug Manager’s 2026 Top 100 Innovative Pharmaceutical Enterprises in China
· Ascentage Pharma, Tiangang Medical
Recognized as a Hangzhou “Good Seedling” Enterprise
· Westlake Omi
Appointed as Head of the Artificial Intelligence Department, 4th Executive Committee of CCI
· Zhu Rui, Chairman of Vivolight
Honored as Top 100 in R&D Strength for Chemical Drugs in 2026
· Beta Pharma
Honored as One of the Top 100 Seed Enterprises in China’s Pharmaceutical Innovation for 2026
· Highlightll Pharma
Yifeng Capital
China's Equity Investment Industry: Venture Capital Firms
Zhu Pai, CEO of Yifeng Capital
2026 China's Best Young Investment Figures
Yifeng Mingyuan Seed Fund Lands in Guangming
· On June 10, Shenzhen Yifeng Mingyuan Seed Venture Capital Partnership (Limited Partnership), established with equity participation from the Shenzhen Science and Technology Innovation Seed Fund, officially completed its industrial and commercial registration. This marks a critical step for Yifeng Capital in its strategic layout for ultra-early-stage investments.
Multiple Portfolio Companies of Yifeng Capital Present Pivotal Data at ASCO 2026
·June 2, annualThe world’s premier academic conference in oncology—the American Society of Clinical Oncology (ASCO) Annual Meeting—concluded in the United States. Portfolio companies of Yifeng Capital, including Westlake Biopharmaceuticals, ZhenShi Biopharma, Qiyu Biologics, Huahao Zhongtian, Saiyuan Biotech, Ascentage Therapeutics, and Chipscreen Biosciences, presented significant clinical research findings.
✦
Recommended Reading
✦
Northin Life's STAR Market IPO
✦
Recommended Reading
✦
Northin Life's STAR Market IPO
Northin Life's STAR Market IPO
Heyuan Biology's IPO on the STAR Market
Bokang Shiyun's IPO on the Main Board of the Hong Kong Stock Exchange
Shenghe Biotech's Main Board IPO in Hong Kong
Quanxin Biologics’ IPO on the Main Board of the Hong Kong Stock Exchange
Swimming Against the Current, Moving Forward with Time
3D Medicines' IPO on the Main Board of the Hong Kong Stock Exchange
Obio Technology's IPO on the STAR Market
Ten Years Honing the Sword, Unsheathed with Razor Sharpness
Yahong Medicine's STAR Market IPO
Looking forward to your
Share
Like
Watching
Heyuan Biology's IPO on the STAR Market
Heyuan Biology's IPO on the STAR Market
Heyuan Biology's IPO on the STAR Market
Bokang Shiyun's IPO on the Main Board of the Hong Kong Stock Exchange
Bokang Shiyun's IPO on the Main Board of the Hong Kong Stock Exchange
Shenghe Biotech's Main Board IPO in Hong Kong
Quanxin Biologics’ IPO on the Main Board of the Hong Kong Stock Exchange
Swimming Against the Current, Moving Forward with Time
3D Medicines' IPO on the Main Board of the Hong Kong Stock Exchange
Obio Technology's IPO on the STAR Market
Ten Years Honing the Sword, Unsheathed with Razor Sharpness
Yahong Medicine's STAR Market IPO
Looking forward to your
Share
Like
Watching